Beximco Pharmaceuticals, the Bangladesh-based manufacturer of generic pharma products and APIs, has launched the world’s first generic remdesivir for treating COVID-19.
Remdesivir is an antiviral drug that was recently granted Emergency Use Authorisation by the US FDA Food for the treatment of COVID-19.
The launch the grant of Emergency Use Authorisation by the Directorate General of Drug Administration (DGDA) – the regulatory authority in Bangladesh – for Beximco Pharma’s remdesivir IV injection (under the brand name Bemsivir) received on 21 May 2020.
Emergency approvals will help to broaden the use of remdesivir in hospitalised patients, especially in developing and least developed countries where access to breakthrough, advanced drugs remains a major challenge.
Originally developed by Gilead Sciences, remdesivir is a direct acting antiviral drug that inhibits viral RNA synthesis. Remdesivir is administered intravenously and is authorised for the treatment of hospitalised patients with severe COVID-19 disease.
Recent clinical trials have shown evidence that remdesivir helps severe COVID-19 patients recover faster.
Beximco Pharma is donating remdesivir (Bemsivir) to the Bangladesh Government for supply only to Government hospitals free of charge. Remdesivir (Bemsivir) will not be available through retail pharmacies, in compliance with the directives from the DGDA.